New Breakthrough Allows Legally Blind Patients to Read Again with Tiny Implant and Special Glasses
In a groundbreaking study published in the New England Journal of Medicine, scientists have made a remarkable discovery that's giving hope to millions of people worldwide living with geographic atrophy, an advanced form of dry macular degeneration. A tiny implant thinner than human hair has been implanted into the back of the eyes of 32 patients with this condition, resulting in "meaningful improvement" in visual acuity for 26 out of 32 participants after just 12 months.
The innovative treatment involves inserting a miniature device called PRIMA (photovoltaic retina implant microarray) under the retina and wearing special glasses equipped with a video camera that projects near-infrared light to enhance vision. The treatment has been shown to restore visual acuity in patients who have lost their central vision due to geographic atrophy.
One patient, 70-year-old Sheila Irvine, described her experience with PRIMA as "out of this world," saying it's "beautiful and wonderful" to be able to read and do crosswords again. However, she noted that the treatment requires a lot of concentration and can only focus on specific letters at a time.
Geographic atrophy is the leading cause of blindness in older adults, affecting approximately 5 million people worldwide. Until now, there was no treatment available to improve patients' ability to read or recognize faces. The FDA-approved medication Syfovre, which slows down disease progression but does not reverse it, has been a significant breakthrough in recent years.
The PRIMA implant is made by California-based biotech company Science Corporation and is not yet licensed for widespread use. While the clinical study's results are promising, the CEO of Science Corporation emphasized that this technology still holds great promise for revolutionizing vision restoration for patients with geographic atrophy.
While more research is needed to fully understand the long-term effects of PRIMA, this breakthrough offers a glimmer of hope for millions of people living with this debilitating condition.
In a groundbreaking study published in the New England Journal of Medicine, scientists have made a remarkable discovery that's giving hope to millions of people worldwide living with geographic atrophy, an advanced form of dry macular degeneration. A tiny implant thinner than human hair has been implanted into the back of the eyes of 32 patients with this condition, resulting in "meaningful improvement" in visual acuity for 26 out of 32 participants after just 12 months.
The innovative treatment involves inserting a miniature device called PRIMA (photovoltaic retina implant microarray) under the retina and wearing special glasses equipped with a video camera that projects near-infrared light to enhance vision. The treatment has been shown to restore visual acuity in patients who have lost their central vision due to geographic atrophy.
One patient, 70-year-old Sheila Irvine, described her experience with PRIMA as "out of this world," saying it's "beautiful and wonderful" to be able to read and do crosswords again. However, she noted that the treatment requires a lot of concentration and can only focus on specific letters at a time.
Geographic atrophy is the leading cause of blindness in older adults, affecting approximately 5 million people worldwide. Until now, there was no treatment available to improve patients' ability to read or recognize faces. The FDA-approved medication Syfovre, which slows down disease progression but does not reverse it, has been a significant breakthrough in recent years.
The PRIMA implant is made by California-based biotech company Science Corporation and is not yet licensed for widespread use. While the clinical study's results are promising, the CEO of Science Corporation emphasized that this technology still holds great promise for revolutionizing vision restoration for patients with geographic atrophy.
While more research is needed to fully understand the long-term effects of PRIMA, this breakthrough offers a glimmer of hope for millions of people living with this debilitating condition.